Molecular Biology

Scientific Imagers

Camera

Featuring a 24 megapixel coloured digital camera with a superfast autofocus lens inside a dust resistant enclosure, which can be controlled from a PC or a touchscreen. Live view images and capture times of less than a few seconds provides efficient imaging. Gel image acquisition and control software has full function control panel which allows user to adjust camera and lens settings like exposure time settings, focus and aperture (iris). Histogram display on the screen shows image saturation.

Low Noise CMOS imaging sensor
8-bit and 14-bit options
24 megapixel camera
Sharp Zoom lens
Motorized auto-focus
Motorized aperture setting
Manual zoom range 3x
Exposure from 0.00025s onwards
Single/Dual 312nm/365nm/254nm UV
RGB LEDs and convertor screens
Operate camera via PC
Timer for auto-off of UV
Advanced Gel Analysis Software
 

Darkroom Cabinet

The epoxy coated, chemical & corrosion resistant light-tight cabinet has filter holder (1, 3 or 7 filter holder), a UV safety switch and a roll-out transilluminator. The safety switch switches off UV lights as soon as the door is opened. Options for front viewing window with two side windows on the cabinet for excision of bands are also available.

 

Illumination

Standard lighting systems are UV transillumination in 302-312nm* and Epi-white light
Gel filter illumination area is 20x20cm, with 21x26cm option for larger gels. For extra large gels, we also offer a 26x26cm filter.
Gels up to a maximum of 26x26cm can be observed, captured and analysed
Sample size area is 38x30cm
We also offer UV transillumination in dual wavelength (312+365nm being most common)
For rare applications UV transillumination in triple wavelength (254+312+365nm) can also be given
Multi broad band wavelengths can also be offered 254nm, 312nm and 365nm UV trans lights
Intensity control for low and high trans-illumination - low for preparative work and high for quantitative
White light tables are optional to use gel doc for protein gels documentation
For special stains, blue light tables can also be given
Multi-wavelength epi-illumination LEDs are also available for Red, Green, Blue lights for special stains
* Please note that 300nm, 302nm, 306nm and 312nm are in the same range of wavelengths called UV-B (also known as mid-range). Some manufacturers quote 302nm but it is the same as 312nm..

 

Transillumination

Ultraviolet transillumination can be provided in 302-312nm, 365nm or 254nm individual ranges or as Dual or Triple options. Filter size of transilluminator is 20x20 cm, optionally 21x26cm can be provided too. Low & high intensity of 70% & 100% on the transilluminator provides an easy switch between preparative & final imaging. A timer is attached to the transilluminator, which auto switches off UV light in case the user forgets to turn it off. This increases the life of the UV lamps. Trans White & Trans Blue light tables are also available.

 

Epillumination

Epi-white light illumination through dual LED tubes from above is standard. Ultraviolet epi-illumination in a variety of wavelengths can also be provided. For specific stains, epi-light in blue, green or red LEDs can be provided. A combination of all these illumination modes in the same system can be provided.

 

Filter Holder

Standard is manual single position filter holder
Advanced models with 3, 4 and 7-position manual and motorized filter holder are also available
Orange 590 EtBr and clear are standard

Filters

Orange 590: Ethidium Bromide (EtBr), SYPRO Ruby, ProQ Diamond, Deep Purple, etc
Green 520: SYBR Green I, Green II, SYBR Gold, GFP, Fluorescein, FITC
Orange 560: SYBR Safe, Rhodamine, Cy3, etc
Red 630: SYPRO Red, Texas Red, etc
Blue 480: Hoechst, Coumarin, etc
Clear: Coomassie Blue, Silver etc
 

How the Gel Documentation & Imaging Analysis System works

A transilluminator is mounted on roll-out rails inside a light-tight cabinet. To place the gel, the door is opened and transilluminator pulled out. Push it in, close the door and switch on the UV light and camera. The camera is mounted on top of the cabinet along with zoom lens and wavelenght filter (nominally 590nm filter suitable for Ethidium Bromide EtBr gels is provided).

Connect the camera to the PC using the USB cable and gel capture software, to get a real-time live view image of the gel. Adjust camera settings (like shutter speed, aperture, focus) till the optimum image is obtained. Click your images and save them on the PC. A white light epi-illuminations source is also provided, that illuminates objects from top.

With the optional 1D gel analysis software, you can analyse the gels.

 

Package Includes

Dark room cabinet with safety switch
Roll out variable intensity 312nm transilluminator
Epi-white light illumination
24 megapixel camera
Gel capture software
590nm filter, suitable for EtBr stained gels
Power cords, USB cable, instruction manual, warranty card

Gel Documentation Systems

Aging (Aging-US)

Aging-US published this research paper as the cover of Volume 14, Issue 21, entitled, "IGF1 gene therapy in middle-aged female rats delays reproductive senescence through its effects on hypothalamic GnRH and kisspeptin neurons" by researchers from the Laboratorio de Bioquímica del Envejecimiento, Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP), Facultad de Ciencias Médicas, UNLP-CONICET, La Plata, Argentina; Laboratorio de Histología y Embriología Descriptiva, Experimental y Comparada, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, La Plata, Argentina; Instituto de Farmacología Experimental de Córdoba-CONICET, Departamento de Farmacología, Facultad de Ciencias Químicas, UNC-CONICET, Córdoba, Argentina; Department of Anatomy, Histology and Neuroscience, Autonomous University of Madrid, Madrid, España; Instituto Cajal, CSIC, Madrid, España; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Madrid, España.

DOI - https://doi.org/10.18632/aging.204360

Corresponding authors - Maria-Angeles Arevalo - arevalo@cajal.csic.es, and María José Bellini - mariajosebellini@med.unlp.edu.ar

Abstract

The process of aging is the result of progressive loss of homeostasis and functional body impairment, including the central nervous system, where the hypothalamus plays a key role in regulating aging mechanisms. The consequences of aging include a chronic proinflammatory environment in the hypothalamus that leads to decreased secretion of gonadotropin-releasing hormone (GnRH) and impairs kisspeptin neuron functionality.

In this work, we investigated the effect of insulin-like growth factor 1 (IGF1) gene therapy on hypothalamic kisspeptin/GnRH neurons and on microglial cells, that mediate the inflammatory process related with the aging process. The results show that IGF1 rats have higher kisspeptin expression in the anteroventral periventricular (AVPV) nucleus and higher immunoreactivity of GnRH in the arcuate nucleus and median eminence. In addition, IGF1-treated animals exhibit increased numbers of Iba1+ microglial cells and MHCII+/Iba1+ in the AVPV and arcuate nuclei. In conclusion, IGF1 gene therapy maintains kisspeptin production in the AVPV nucleus, induces GnRH release in the median eminence, and alters the number and reactivity of microglial cells in middle-aged female rats. We suggest that IGF1 gene therapy may have a protective effect against reproductive decline.

Sign up for free Altmetric alerts about this article - 
https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204360

Keywords - aging, IGF1, gene therapy, reproductive senescence, GnRH, kisspeptin, microglia

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at https://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us
Facebook - https://www.facebook.com/AgingUS/
Twitter - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/agingus​
LinkedIn - https://www.linkedin.com/company/aging/
Pinterest - https://www.pinterest.com/AgingUS/

Media Contact
18009220957
MEDIA@IMPACTJOURNALS.COM

IGF1 Gene Therapy in Middle-Aged Female Rats Delays Reproductive Senescence

Oncotarget

Oncotarget published this trending research paper in Volume 13, entitled, "MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway" by researchers from Thoracic Oncology, Department of Medicine, University of California, San Francisco, CA; Touro University, College of Osteopathic Medicine, Vallejo, CA.

DOI - https://doi.org/10.18632/oncotarget.28305

Correspondence to - Jen-Chieh Lee - jenchieh.lee@ucsf.edu , Shu Liu - shu.liu@ucsf.edu 

Abstract

Acute myeloid leukemia (AML) is the most lethal form of AML due to disease relapse. Cyclin dependent kinase 8 (CDK8) is a serine/threonine kinase that belongs to the family of Cyclin-dependent kinases and is an emerging target for the treatment of AML. MK256, a potent, selective, and orally available CDK8 inhibitor was developed to target AML. We sought to examine the anticancer effect of MK256 on AML. In CD34+/CD38- leukemia stem cells, we found that MK256 induced differentiation and maturation. Treatment of MK256 inhibited proliferation of AML cell lines. Further studies of the inhibitory effect suggested that MK256 not only downregulated phosphorylated STAT1(S727) and STAT5(S726), but also lowered mRNA expressions of MCL-1 and CCL2 in AML cell lines. Efficacy of MK256 was shown in MOLM-14 xenograft models, and the inhibitory effect on phosphorylated STAT1(S727) and STAT5(S726) with treatment of MK256 was observed in vivo. Pharmacologic dynamics study of MK256 in MOLM-14 xenograft models showed dose-dependent inhibition of the STAT pathway. Both in vitro and in vivo studies suggested that MK256 could effectively downregulate the STAT pathway. In vitro ADME, pharmacological kinetics, and toxicity of MK256 were profiled to evaluate the drug properties of MK256. Our results show that MK256 is a novel CDK8 inhibitor with a desirable efficacy and safety profile and has great potential to be a promising drug candidate for AML through regulating the STAT pathway.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28305

Press release - https://www.oncotarget.com/index.php?journal=oncotarget&page=news&op=press&item=oncotarget-mk-is-novel-cdk-inhibitor-with-potent-antitumor-activity-in-aml-through-downregulation-of-stat-pathway

Keywords - AML, CDK8, kinase inhibitor, STAT pathway, xenograft

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/OncotargetYouTube
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

MK256 is a Novel CDK8 Inhibitor With Potent Antitumor Activity in AML

Aging (Aging-US) published this trending research paper in Volume 14, Issue 20, entitled, “Age-associated changes in microglia activation and Sirtuin-1- chromatin binding patterns” by researchers from San Diego Biomedical Research Institute, San Diego, CA; University of Nebraska Medical Center, Omaha, NE; Oncovalent Therapeutics, Los Angeles, CA.

DOI - https://doi.org/10.18632/aging.204329

Corresponding author - Maria Cecilia Garibaldi Marcondes - cmarcondes@SDBRI.org 

ABSTRACT

The aging process is associated with changes in mechanisms maintaining physiology, influenced by genetics and lifestyle, and impacting late life quality and longevity. Brain health is critical in healthy aging. Sirtuin 1 (Sirt1), a histone deacetylase with silencing properties, is one of the molecular determinants experimentally linked to health and longevity. We compared brain pathogenesis and Sirt1-chromatin binding dynamics in brain pre-frontal cortex from 2 groups of elder rhesus macaques, divided by age of necropsy: shorter-lived animals (18-20 years old (yo)), equivalent to 60-70 human yo; and longer-lived animals (23-29 yo), corresponding to 80-100 human yo and modeling successful aging. These were compared with young adult brains (4-7 yo). Our findings indicated drastic differences in the microglia marker Iba1, along with factors influencing Sirt1 levels and activity, such as CD38 (an enzyme limiting NAD that controls Sirt1 activity) and mir142 (a microRNA targeting Sirt1 transcription) between the elder groups. Iba1 was lower in shorter-lived animals than in the other groups, while CD38 was higher in both aging groups compared to young. mir142 and Sirt1 levels were inversely correlated in longer-lived brains (>23yo), but not in shorter-lived brains (18-20 yo). We also found that Sirt1 binding showed signs of better efficiency in longer-lived animals compared to shorter-lived ones, in genes associated with nuclear activity and senescence. Overall, differences in neuroinflammation and Sirt1 interactions with chromatin distinguished shorter- and longer-lived animals, suggesting the importance of preserving microglia and Sirt1 functional efficiency for longevity.

Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204329

Press release - https://www.aging-us.com/news_room/age-associated-changes-in-microglia-activation-and-sirtuin-1-chromatin-binding-patterns

Keywords - aging, brain, rhesus macaques, microglia, Sirtuin-1

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at http://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us
Facebook - https://www.facebook.com/AgingUS/
Twitter - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/agingus​
LinkedIn - https://www.linkedin.com/company/aging/
Pinterest - https://www.pinterest.com/AgingUS/

Aging-US is published by Impact Journals, LLC: http://www.ImpactJournals.com​​

Media Contact
18009220957
MEDIA@IMPACTJOURNALS.COM

Age-Associated Changes in Microglia Activation and Sirtuin-1- Chromatin Binding Patterns

Oncotarget published this research paper in Volume 13, entitled, "Tumor hyaluronan as a novel biomarker in non-small cell lung cancer: A retrospective study" by researchers from Gastrointestinal and Neuroendocrine Malignancies, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA; Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, CA; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA; Department of Radiation Oncology, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Lung Cancer Research Program, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA.

DOI - https://doi.org/10.18632/oncotarget.28304

Correspondence to - Andrew E. Hendifar - andrew.hendifar@cshs.org 

Abstract

Introduction: Hyaluronan (HA) accumulation is associated with tumorigenesis and aggressive tumor behavior.

Aims: We investigated the biomarker potential of HA in non-small cell lung cancer (NSCLC).

Methods: HA levels were scored using affinity histochemistry in 137 NSCLC samples stratified by HA score ≤10, 11–20, 21–30, and >30 with HA-high defined as ≥25% expression in the extracellular matrix (ECM) of the tumor surface area. Overall survival (OS) and time to progression from initiation of taxane therapy (TTP) were compared using log-rank tests based on HA score.

Results: Of 122 patients with recurrent/metastatic NSCLC, 93 had mean HA scores that were not significantly different across clinicopathologic variables. Frequency of HA-high tumors did not differ by histology (34/68 adenocarcinomas vs. 12/25 squamous tumors, Fisher’s p = 1.0000). Median OS for recurrent/metastatic adenocarcinoma was 35.5 months (95%, 23.6–50.3) vs. 17.9 months for squamous (95%, 12.7–37.0, log-rank test, p = 0.0165). OS was not significantly different by HA quartiles, high or low (<25) HA score and tumor histology, and HA biopsy site (all p > 0.05). Median TTP (n = 98) significantly differed by HA quartile (2.8 months for HA score ≤10; 5.0 months for 11–20; 7.9 months for 21–30; 3.9 months for >30, p = 0.0265). Improved TTP trended in HA-high over HA-low tumors (n = 98, p = 0.0911).

Conclusion: In this NSCLC cohort, tumor HA level represents a potential biomarker for TTP, which remains a cornerstone of NSCLC therapy. Further validation is warranted to identify the HA accumulation threshold associated with clinical benefit.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28304

Press release - https://www.oncotarget.com/index.php?journal=oncotarget&page=news&op=press&item=oncotarget-tumor-hyaluronan-as-novel-biomarker-in-non-small-cell-lung-cancer-a-retrospective-study

Keywords - hyaluronan, hyaluronic acid, biomarker, prognostic, predictive

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/OncotargetYouTube
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Tumor Hyaluronan as Novel Non-Small Cell Lung Cancer Biomarker: Retrospective Study

Aging (Aging-US) published this trending research perspective in Volume 14, Issue 20, entitled, “Lamin A to Z in normal aging” by researchers from Independent Affiliation, Lauderhill, FL; The Buck Institute for Research on Aging, Novato, CA; Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Healthy Longevity, National University Health System, Singapore; Departments of Biochemistry and Physiology, Yong Loo Lin School of Medicine, National University of Singapore.
#aging #openaccess #mutation #lifespan #research

DOI - https://doi.org/10.18632/aging.204342

Corresponding author - Brian K. Kennedy - bkennedy@nus.edu.sg 

Abstract

Almost since the discovery that mutations in the LMNA gene, encoding the nuclear structure components lamin A and C, lead to Hutchinson-Gilford progeria syndrome, people have speculated that lamins may have a role in normal aging. The most common HPGS mutation creates a splice variant of lamin A, progerin, which promotes accelerated aging pathology. While some evidence exists that progerin accumulates with normal aging, an increasing body of work indicates that prelamin A, a precursor of lamin A prior to C-terminal proteolytic processing, accumulates with age and may be a driver of normal aging. Prelamin A shares properties with progerin and is also linked to a rare progeroid disease, restrictive dermopathy. Here, we describe mechanisms underlying changes in prelamin A with aging and lay out the case that this unprocessed protein impacts normative aging. This is important since intervention strategies can be developed to modify this pathway as a means to extend healthspan and lifespan.

Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204342

Press release - https://www.aging-us.com/news_room/lamin-a-to-z-in-normal-aging

Keywords - lamin A, prelamin A, zmpste24, mTOR, aging

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at http://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us
Facebook - https://www.facebook.com/AgingUS/
Twitter - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/agingus​
LinkedIn - https://www.linkedin.com/company/aging/
Pinterest - https://www.pinterest.com/AgingUS/

Aging-US is published by Impact Journals, LLC: http://www.ImpactJournals.com​​

Media Contact
18009220957
MEDIA@IMPACTJOURNALS.COM

Paper Spotlight: Lamin A to Z in Normal Aging

Aging (Aging-US) published this trending research perspective in Volume 14, Issue 20, entitled, “Rapamycin treatment early in life reprograms aging: hyperfunction theory and clinical practice” by Dr. Blagosklonny from Roswell Park Comprehensive Cancer Center, Buffalo, NY.

DOI - https://doi.org/10.18632/aging.204354

Corresponding author - Mikhail V. Blagosklonny - Blagosklonny@oncotarget.com 

ABSTRACT

Making provocative headlines, three outstanding publications demonstrated that early-life treatment with rapamycin, including treatments during developmental growth, extends lifespan in animals, confirming predictions of hyperfunction theory, which views aging as a quasi-program (an unintended continuation of developmental growth) driven in part by mTOR. Despite their high theoretical importance, clinical applications of two of these studies in mice, Drosophila and Daphnia cannot be implemented in humans because that would require growth retardation started at birth. A third study demonstrated that a transient (around 20% of total lifespan in Drosophila) treatment with rapamycin early in Drosophila adult life is as effective as lifelong treatment, whereas a late-life treatment is not effective. However, previous studies in mice demonstrated that a transient late-life treatment is highly effective. Based on hyperfunction theory, this article attempts to reconcile conflicting results and suggests the optimal treatment strategy to extend human lifespan.

Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204354

Keywords - aging, senescence, gerostatics, geroscience, sirolimus, healthspan

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at http://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us
Facebook - https://www.facebook.com/AgingUS/
Twitter - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/agingus​
LinkedIn - https://www.linkedin.com/company/aging/
Pinterest - https://www.pinterest.com/AgingUS/

Aging-US is published by Impact Journals, LLC: http://www.ImpactJournals.com​​

Media Contact
18009220957
MEDIA@IMPACTJOURNALS.COM

Rapamycin Treatment Early in Life Reprograms Aging: Hyperfunction Theory and Clinical Practice

Dr. Ya-Jen Chiu from the Department of Life Science at National Taiwan Normal University in Taipei, discusses a research paper she co-authored that was published by Aging (Aging-US) in Volume 14, Issue 18, entitled, “Novel TRKB agonists activate TRKB and downstream ERK and AKT signaling to protect Aβ-GFP SH-SY5Y cells against Aβ toxicity.”

DOI - https://doi.org/10.18632/aging.204306

Corresponding authors - Chiung-Mei Chen - cmchen@cgmh.org.tw, Ying-Chieh Sun - sun@ntnu.edu.tw, Guey-Jen Lee-Chen - t43019@ntnu.edu.tw

Abstract

Decreased BDNF and impaired TRKB signaling contribute to neurodegeneration in Alzheimer's disease (AD). We have shown previously that coumarin derivative LM-031 enhanced CREB/BDNF/BCL2 pathway. In this study we explored if LM-031 analogs LMDS-1 to -4 may act as TRKB agonists to protect SH-SY5Y cells against Aβ toxicity. By docking computation for binding with TRKB using 7,8-DHF as a control, all four LMDS compounds displayed potential of binding to domain d5 of TRKB. In addition, all four LMDS compounds exhibited anti-aggregation and neuroprotective efficacy on SH-SY5Y cells with induced Aβ-GFP expression. Knock-down of TRKB significantly attenuated TRKB downstream signaling and the neurite outgrowth-promoting effects of these LMDS compounds. Among them, LMDS-1 and -2 were further examined for TRKB signaling. Treatment of ERK inhibitor U0126 or PI3K inhibitor wortmannin decreased p-CREB, BDNF and BCL2 in Aβ-GFP cells, implicating the neuroprotective effects are via activating TRKB downstream ERK, PI3K-AKT and CREB signaling. LMDS-1 and -2 are blood-brain barrier permeable as shown by parallel artificial membrane permeability assay. Our results demonstrate how LMDS-1 and -2 are likely to work as TRKB agonists to exert neuroprotection in Aβ cells, which may shed light on the potential application in therapeutics of AD.

Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204306

Keywords - aging, Alzheimer’s disease, TRKB agonists, Aβ, neuroprotection, therapeutics

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at https://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us
Facebook - https://www.facebook.com/AgingUS/
Twitter - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/agingus​
LinkedIn - https://www.linkedin.com/company/aging/
Pinterest - https://www.pinterest.com/AgingUS/

Media Contact
18009220957
MEDIA@IMPACTJOURNALS.COM

Behind the Study: Novel TRKB Agonists Activate TRKB and Downstream ERK and AKT Signaling

Oxford Nanopore Technologies

Take your sequencing to the next level with the recently released PromethION 2 devices. They enable flexible, high-yield sequencing, in a compact, accessible design. The devices are designed for users with sample processing requirements of up to four full-length sequencing runs per week / ~200 flow cells per year. Each flow cell can deliver hundreds of gigabases of nanopore sequencing data. With this sequencing capacity, you can obtain the data you need for completing large genomes, studying complex metagenomic samples, obtaining known and novel transcripts from single-cell sequencing, and much more.

[url][link]https://nanoporetech.com/resource-centre/promethion-2-brochure?utm_campaign=P2%202022&utm_source=tech_networks&utm_medium=video[/link][name]Download the PromethION 2 brochure[/name][/url]

[url][link]https://nanoporetech.com/products/promethion-2?utm_campaign=P2%202022&utm_source=tech_networks&utm_medium=video[/link][name]Browse the PromethION 2 page[/name][/url]


Molecular Biology

Refine By

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.